Bussiness
Deloitte acquires End Point’s disease surveillance business assets
Deloitte, which provides consulting, financial advisory, industry insights and audits, tax services and risk-management services to various industries, announced it had acquired a substantial number of End Point’s assets related to CasePointer, its disease-surveillance business.
CasePointer utilizes open-source public health software to create tools and automate processes for state and local public health agencies related to epidemiologic needs and disease surveillance.
Deloitte will use EndPoint’s CasePointer services with its GovConnect digital assets, which include public-sector digital modules and AI copilots that assist government agencies with technology related to communicable disease, bioterrorism events and environmental hazards.
CasePointer’s software engineers, DevOps engineers, cloud developers, former public health officials and epidemiologists will join Deloitte.
“The acquisition of End Point’s CasePointer business builds on Deloitte’s ongoing investments, complements our customizable and human-centered solutions, and supports our growth into new markets,” Jason Salzetti, principal at Deloitte Consulting, and Deloitte’s government and public services industry leader, said in a statement.
“It also underscores our commitment to IndustryAdvantage and to deepening our industry expertise to enhance the mission-critical work we deliver for our public health clients.”
THE LARGER TREND
In September, Deloitte announced it was adding generative AI technology to its tools for health and human services agencies to help them modernize legacy platforms and improve individuals’ experiences with government programs.
Another company focused on the public health sector is Syra Health, which has scored numerous contracts with various local and state agencies within the last year.
The company announced a five-year agreement with the City of San Antonio in November, its home state of Indiana in January, Virginia in February and Washington in May.